Parallax Volatility Advisers
FBIO icon

Parallax Volatility Advisers’s Fortress Biotech FBIO Stock Holding History

Parallax Volatility Advisers’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-339
Closed -$20K – 2820
2017
Q4 		$20K Buy
+339
New +$20K ﹤0.01% 3666

Other funds holding FBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CL
CPWM LLC Seattle, Washington $1.06B AUM 14.49% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Parallax Volatility Advisers's FBIO Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of Fortress Biotech (FBIO) in Q1 2018, closing a stake of 339 shares — an estimated $20K sold.

Parallax Volatility Advisers first reported a position in FBIO in Q4 2017 and held it in 1 quarter. The position peaked at $20K in Q4 2017. 66 funds tracked by Wall St. Rank hold FBIO as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining Fortress Biotech position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 339 Fortress Biotech shares in Q1 2018, an estimated $20K.
  • Parallax Volatility Advisers first reported a position in Fortress Biotech in Q4 2017 and held it in 1 quarter.
  • Parallax Volatility Advisers's Fortress Biotech position peaked at $20K in Q4 2017.
  • 66 funds tracked by Wall St. Rank held Fortress Biotech as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.